Docoh
Loading...

GSK Glaxosmithkline

 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
Form 6-K
 
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
 
 
 
For the month of April 2020
 
Commission File Number 001-15170
 
 
GlaxoSmithKline plc
(Translation of registrant's name into English)
 
 
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive office)
 
 
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
 
Form 20-F . . . .X. . . . Form 40-F . . . . . . . .
 
 
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
 
GlaxoSmithKline plc (the 'Company')
Transaction notification
 
1.Details of PDMR/person closely associated with them ('PCA')
a)NameMs E Walmsley
b)Position/statusChief Executive Officer
c)
Initial notification/
amendment
Initial notification
2.Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)NameGlaxoSmithKline plc
b)LEI5493000HZTVUYLO1D793
3.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 
b)Nature of the transactionAcquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 April 2020.
c)Price(s) and volume(s) Price(s)Volume(s) 
 £15.67852,407.338 
    
d)
Aggregated information
 
 
N/A (single transaction)
Aggregated volume Price 
e)Date of the transaction2020-04-14
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
 
1.Details of PDMR/person closely associated with them ('PCA')
a)NameMr R Connor
b)Position/statusPresident, Global Vaccines
c)
Initial notification/
amendment
Initial notification
2.Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)NameGlaxoSmithKline plc
b)LEI5493000HZTVUYLO1D793
3.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 
b)Nature of the transactionAcquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 April 2020.
c)Price(s) and volume(s) Price(s)Volume(s) 
 £15.6785
1,499.016
 
 
    
d)
Aggregated information
 
 
N/A (single transaction)
Aggregated volume Price 
e)Date of the transaction2020-04-14
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
 
1.Details of PDMR/person closely associated with them ('PCA')
a)NameMs D Conrad
b)Position/statusSVP, Human Resources
c)
Initial notification/
amendment
Initial notification
2.Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)NameGlaxoSmithKline plc
b)LEI5493000HZTVUYLO1D793
3.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 
b)Nature of the transactionAcquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 April 2020.
c)Price(s) and volume(s) Price(s)Volume(s) 
 £15.6785
9.409
 
 
    
d)
Aggregated information
 
 
N/A (single transaction)
Aggregated volume Price 
e)Date of the transaction2020-04-14
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
 
1.Details of PDMR/person closely associated with them ('PCA')
a)NameMr J Ford
b)Position/statusSVP & General Counsel
c)
Initial notification/
amendment
Initial notification
2.Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)NameGlaxoSmithKline plc
b)LEI5493000HZTVUYLO1D793
3.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)Description of the financial instrument
American Depositary Shares ('ADSs')
ISIN: US37733W1053
 
b)Nature of the transactionAcquisition of ADSs following the re-investment of dividends paid to shareholders on 9 April 2020.
c)Price(s) and volume(s) Price(s)Volume(s) 
 $38.8036
88.183
 
 
 
    
d)
Aggregated information
 
N/A (single transaction)
Aggregated volume Price 
e)Date of the transaction2020-04-13
4f)
Place of the transaction
 
New York Stock Exchange (XNYS)
 
 
 
1.Details of PDMR/person closely associated with them ('PCA')
a)NameMr J Ford
b)Position/statusSVP & General Counsel
c)
Initial notification/
amendment
Initial notification
2.Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)NameGlaxoSmithKline plc
b)LEI5493000HZTVUYLO1D793
3.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 
b)Nature of the transactionAcquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 April 2020.
c)Price(s) and volume(s) Price(s)Volume(s) 
 £15.6785
0.000033
 
 
 
 
    
d)
Aggregated information
 
 
N/A (single transaction)
Aggregated volume Price 
e)Date of the transaction2020-04-14
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
 
1.Details of PDMR/person closely associated with them ('PCA')
a)NameMr N Hirons
b)Position/statusSVP, Global Ethics & Compliance
c)
Initial notification/
amendment
Initial notification
2.Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)NameGlaxoSmithKline plc
b)LEI5493000HZTVUYLO1D793
3.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)Description of the financial instrument
American Depositary Shares ('ADSs')
ISIN: US37733W1053
 
b)Nature of the transactionAcquisition of ADSs following the re-investment of dividends paid to shareholders on 9 April 2020.
c)Price(s) and volume(s) Price(s)Volume(s) 
 $38.803623.684 
    
d)
Aggregated information
 
 
N/A (single transaction)
Aggregated volume Price 
e)Date of the transaction2020-04-13
f)
Place of the transaction
 
New York Stock Exchange (XNYS)
 
 
 
1.Details of PDMR/person closely associated with them ('PCA')
a)NameMr N Hirons
b)Position/statusSVP, Global Ethics & Compliance
c)
Initial notification/
amendment
Initial notification
2.Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)NameGlaxoSmithKline plc
b)LEI5493000HZTVUYLO1D793
3.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 
b)Nature of the transactionAcquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 April 2020.
c)Price(s) and volume(s) Price(s)Volume(s) 
 £15.6785
873.574
 
 
 
 
 
    
d)
Aggregated information
 
 
N/A (single transaction)
Aggregated volume Price 
e)Date of the transaction2020-04-14
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
 
1.Details of PDMR/person closely associated with them ('PCA')
a)NameMr L Miels
b)Position/statusPresident, Global Pharmaceuticals
c)
Initial notification/
amendment
Initial notification
2.Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)NameGlaxoSmithKline plc
b)LEI5493000HZTVUYLO1D793
3.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 
b)Nature of the transactionAcquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 April 2020.
c)Price(s) and volume(s) Price(s)Volume(s) 
 £15.6785
3,010.736
 
 
 
    
d)
Aggregated information
 
 
N/A (single transaction)
Aggregated volume Price 
e)Date of the transaction2020-04-14
4f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
 
1.Details of PDMR/person closely associated with them ('PCA')
a)NameMs S Jackson
b)Position/statusSVP, Global Communications and CEO Office
c)
Initial notification/
amendment
Initial notification
2.Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)NameGlaxoSmithKline plc
b)LEI5493000HZTVUYLO1D793
3.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 
b)Nature of the transactionAcquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 April 2020.
c)Price(s) and volume(s) Price(s)Volume(s) 
 £15.6785
228.828
 
 
 
 
    
d)
Aggregated information
 
 
N/A (single transaction)
Aggregated volume Price 
e)Date of the transaction2020-04-14
4f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
 
1.Details of PDMR/person closely associated with them ('PCA')
a)NameMr D Jackson
b)Position/statusPCA of Ms S Jackson (SVP, Global Communications and CEO Office)
c)
Initial notification/
amendment
Initial notification
2.Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)NameGlaxoSmithKline plc
b)LEI5493000HZTVUYLO1D793
3.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 
b)Nature of the transactionAcquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 April 2020.
c)Price(s) and volume(s) Price(s)Volume(s) 
 £15.6785
108.238
 
 
 
 
 
    
d)
Aggregated information
 
 
N/A (single transaction)
Aggregated volume Price 
e)Date of the transaction2020-04-14
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
 
1.Details of PDMR/person closely associated with them ('PCA')
a)NameMr B McNamara
b)Position/statusCEO, GSK Consumer Healthcare
c)
Initial notification/
amendment
Initial notification
2.Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)NameGlaxoSmithKline plc
b)LEI5493000HZTVUYLO1D793
3.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)Description of the financial instrument
American Depositary Shares ('ADSs')
ISIN: US37733W1053
 
b)Nature of the transactionAcquisition of ADSs following the re-investment of dividends paid to shareholders on 9 April 2020.
c)Price(s) and volume(s) Price(s)Volume(s) 
 $38.8036
1,131.330
 
 
 
 
    
d)
Aggregated information
 
 
N/A (single transaction)
Aggregated volume Price 
e)Date of the transaction2020-04-13
f)
Place of the transaction
 
New York Stock Exchange (XNYS)
 
 
 
1.Details of PDMR/person closely associated with them ('PCA')
a)NameMr D Redfern
b)Position/statusChief Strategy Officer
c)
Initial notification/
amendment
Initial notification
2.Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)NameGlaxoSmithKline plc
b)LEI5493000HZTVUYLO1D793
3.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 
b)Nature of the transactionAcquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 April 2020.
c)Price(s) and volume(s) Price(s)Volume(s) 
 £15.6785
3,905.422
 
 
 
 
    
d)
Aggregated information
 
 
N/A (single transaction)
Aggregated volume Price 
e)Date of the transaction2020-04-14
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
 
1.Details of PDMR/person closely associated with them ('PCA')
a)NameMr R Simard
b)Position/statusPresident, Pharmaceuticals Supply Chain
c)
Initial notification/
amendment
Initial notification
2.Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)NameGlaxoSmithKline plc
b)LEI5493000HZTVUYLO1D793
3.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 
b)Nature of the transactionAcquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 April 2020.
c)Price(s) and volume(s) Price(s)Volume(s) 
 £15.6785
770.138
 
 
 
    
d)
Aggregated information
 
 
N/A (single transaction)
Aggregated volume Price 
e)Date of the transaction2020-04-14
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
 
1.Details of PDMR/person closely associated with them ('PCA')
a)NameMr P Thomson
b)Position/statusPresident, Global Affairs
c)
Initial notification/
amendment
Initial notification
2.Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)NameGlaxoSmithKline plc
b)LEI5493000HZTVUYLO1D793
3.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 
b)Nature of the transactionAcquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 April 2020.
c)Price(s) and volume(s) Price(s)Volume(s) 
 £15.6785
460.192
 
 
 
    
d)
Aggregated information
 
 
N/A (single transaction)
Aggregated volume Price 
e)Date of the transaction2020-04-14
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
 
1.Details of PDMR/person closely associated with them ('PCA')
a)NameMs K Thomson
b)Position/statusPCA of Mr P Thomson (President, Global Affairs)
c)
Initial notification/
amendment
Initial notification
2.Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)NameGlaxoSmithKline plc
b)LEI5493000HZTVUYLO1D793
3.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 
b)Nature of the transactionAcquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 April 2020.
c)Price(s) and volume(s) Price(s)Volume(s) 
 £15.6785
159.820
 
 
 
    
d)
Aggregated information
 
 
N/A (single transaction)
Aggregated volume Price 
e)Date of the transaction2020-04-14
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
 
1.Details of PDMR/person closely associated with them ('PCA')
a)NameMs D Waterhouse
b)Position/statusChief Executive Officer of ViiV Healthcare
c)
Initial notification/
amendment
Initial notification
2.Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)NameGlaxoSmithKline plc
b)LEI5493000HZTVUYLO1D793
3.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 
b)Nature of the transactionAcquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 April 2020.
c)Price(s) and volume(s) Price(s)Volume(s) 
 £15.6785307.779 
    
d)
Aggregated information
 
 
N/A (single transaction)
Aggregated volume Price 
e)Date of the transaction2020-04-14
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
 
 
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
 GlaxoSmithKline plc
 (Registrant)
  
Date: April 16, 2020 
  
 
By:/s/ VICTORIA WHYTE
--------------------------
  
 Victoria Whyte
 Authorised Signatory for and on
 behalf of GlaxoSmithKline plc